Low-density lipoprotein cholesterol-lowering drugs: a narrative review
N Ferri, M Ruscica, S Fazio, A Corsini - Journal of Clinical Medicine, 2024 - mdpi.com
The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo
identified an active compound (compactin) that inhibited cholesterol biosynthesis from the …
identified an active compound (compactin) that inhibited cholesterol biosynthesis from the …
Advances in the pharmacological management of hyperlipidemia through the use of combination therapies
AS Wierzbicki - Expert Opinion on Pharmacotherapy, 2024 - Taylor & Francis
Introduction Lipid-lowering therapies are well established for the treatment of cardiovascular
disease (CVD). Historically monotherapy studies have been performed, but the introduction …
disease (CVD). Historically monotherapy studies have been performed, but the introduction …
The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and prevalence of urinary stones in US adults: a …
H Liu, Y Zhou, M Jin, H Hao, Y Yuan, H Jia - International Urology and …, 2024 - Springer
Background This study examines the association between the non-high-density lipoprotein
cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and urinary stones in …
cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and urinary stones in …
In Silico Identification of Natural Products and World-Approved Drugs Targeting the KEAP1/NRF2 Pathway Endowed with Potential Antioxidant Profile
In this study, we applied a computer-based protocol to identify novel antioxidant agents that
can reduce oxidative stress (OxS), which is one of the main hallmarks of several disorders …
can reduce oxidative stress (OxS), which is one of the main hallmarks of several disorders …
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Cardiovascular disease (CVD) is the leading cause of mortality globally. Low-density
lipoprotein (LDL) plays an important role in CVD pathophysiology. Research has shown the …
lipoprotein (LDL) plays an important role in CVD pathophysiology. Research has shown the …
Lipid clinic experience with bempedoic acid in three UK centres
A Jakubowska, W Al Hasani, J Williams… - Current Medical …, 2024 - Taylor & Francis
Objective Novel lipid-lowering therapies are being introduced. Few studies exist of the real-
world effectiveness of adenosine-tri-phosphate citrate lyase inhibition with bempedoic acid …
world effectiveness of adenosine-tri-phosphate citrate lyase inhibition with bempedoic acid …
[PDF][PDF] Rosuvastatin accelerates the healing process of partial-thickness burn wounds in rats by reducing TNF-α levels
A Marneri, F Mulita, V Leivaditis… - Archives of Medical …, 2024 - amsad.termedia.pl
Introduction: Burn wound healing is a complex, dynamic process that involves a coordinated
cascade of cellular responses and phases. Inflammation, proliferation and remodeling are …
cascade of cellular responses and phases. Inflammation, proliferation and remodeling are …
New drugs for the treatment of hyperlipidemia in statin-intolerant patients-review
W Płonka, M Pelc, G Sitarek, M Żerek… - Journal of Education …, 2024 - apcz.umk.pl
Materials and methods Materials are from a review of recent literature available in PubMed.
To search for articles, we used keywords such as: bempedoic acid, non-statin therapy …
To search for articles, we used keywords such as: bempedoic acid, non-statin therapy …
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
Diabetes Care, 2025 - diabetesjournals.org
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …